DashboardAll companies
Run this on your own research
Healthcare · Drug Manufacturers - Specialty & Generic

Zoetis Inc.

ZTSNYSE$81.03−$0.97 (−1.18%)Market closed

Price Chart

Daily

Key facts

Market Cap
$33.84B
P/E
13.4x
P/B
10.79x
ROE
66.0%

Zoetis Inc.

Healthcare · Drug Manufacturers - Specialty & Generic · FY 2025

Zoetis Inc. is a global leader in the animal healthcare sector, specializing in the development, manufacture, and commercialization of a diverse range of medicines and vaccines for pets and livestock. Originally part of Pfizer, Zoetis spun off in 2013 and has solidified its position as a key player in the industry. The company's portfolio includes products aimed at veterinarians and livestock producers, supporting health and productivity across various animal species. Zoetis's impact is significant in both the companion animal market, which is driven by increasing pet ownership and rising expenditure on pet care, and the livestock market, which benefits from enhancements in productivity and disease management. Zoetis operates in over 100 countries, continuously investing in research and innovation to address the evolving needs of animal health. Its strategic initiatives and partnerships contribute to building a sustainable future for the animal health industry, bolstering Zoetis’s reputation and relevance in the global market.

CEO
Ms. Kristin C. Peck
Employees
13,800
Website
zoetis.com

Company Statistics

Valuation

P/E
13.4x
P/B
10.79x
P/S
3.80x
EV/EBITDA
10.3x
P/FCF
15.7x

Margins

Gross
71.8%
EBITDA
44.1%
Operating
38.0%
Pre-Tax
35.5%
Net
28.2%

Returns

ROA
18.0%
ROE
66.0%
ROIC
24.1%

Growth (CAGR)

Rev 3Yr
5.4%
Rev 5Yr
7.2%
Op Inc 3Yr
7.1%
Net Inc 3Yr
8.2%

Financial Health

Cash & Cash Equivalents
$2.31B
Net Debt
$9.83B
Debt/Equity
364.3%
Interest Cov
—

Profile

Revenue
$9.47B
Shares Out
—
Public markets · Korea, US, Japanalpha-lenz.com · Core by Treasurer
Zoetis Inc. (ZTS) Stock Forecast 2026 $81.03 — Price, Financials & Analyst Targets | AlphaLenz